More people are using medications to lose weight. In the U.S., around 16 million adults use such medications, like Ozempic. However, many stop within a year, mainly due to high costs and the fact that they aren’t always covered by insurance.
But there’s good news: new research shows that tirzepatide (better known as Mounjaro or Zepbound) leads to long-term weight loss, even after three years. Most people gained back no more than five percent of their lost weight during that time.
Tirzepatide works slightly differently than medications like semaglutide (known from Ozempic and Wegovy). It suppresses appetite in two ways and stimulates insulin release.
Several studies show that tirzepatide is more effective than semaglutide. People lost more weight, with some losing more than 20% of their body weight. The risk of diabetes in people with obesity or prediabetes decreased by 94%.
What stands out: tirzepatide works especially well for people without other health issues and for women. Importantly, the weight loss remained stable over a three-year period.
In short: tirzepatide currently seems to be one of the most effective options for long-term weight loss.
Want to know if weight loss medication is right for you? Contact Elysee. Together, we can explore how to best combine it with a healthy lifestyle. Make an appointment through our website or call 0858 200 200.
Source: Best Life
